SE511373C2 - Preparation for the treatment of aphte - Google Patents

Preparation for the treatment of aphte

Info

Publication number
SE511373C2
SE511373C2 SE9704789A SE9704789A SE511373C2 SE 511373 C2 SE511373 C2 SE 511373C2 SE 9704789 A SE9704789 A SE 9704789A SE 9704789 A SE9704789 A SE 9704789A SE 511373 C2 SE511373 C2 SE 511373C2
Authority
SE
Sweden
Prior art keywords
weight
preparation
formulation
treatment
xylitol
Prior art date
Application number
SE9704789A
Other languages
Swedish (sv)
Other versions
SE9704789L (en
SE9704789D0 (en
Inventor
Martin Nils Braennstroem
Kerstin Birgitta Orreby
Original Assignee
Dental Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dental Therapeutics Ab filed Critical Dental Therapeutics Ab
Priority to SE9704789A priority Critical patent/SE511373C2/en
Publication of SE9704789D0 publication Critical patent/SE9704789D0/en
Priority to PCT/SE1998/002366 priority patent/WO1999032132A1/en
Priority to AU19911/99A priority patent/AU1991199A/en
Publication of SE9704789L publication Critical patent/SE9704789L/en
Publication of SE511373C2 publication Critical patent/SE511373C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a preparation for the treatment of aphtae, preferable aphtae stomatitis. The preparation includes: (a) 5.0 - 10.0 % by weight of orange interpenes; (b) 0.1 - 3.0 % by weight of glycyrrhizin; (c) 0.1 - 1.5 % by weight of xylitol; (d) 1.0 - 10.0 % by weight of cocoamphodiacetate. The inventive preparation is administered in the form of mouthwash, paste, tablets, capsules or chewing gum.

Description

511573 10 15 20 25 30 35 2 fattar följande substanser, som aktiva ämnen: a) 5,0-10,0 vikt-% apelsinterpen, b) 0,1-3,0 vikt-% glycyrrhizin, c) 0,1-1,5 vikt-% xylitol, d) 1,0-10,0 vikt-% kokoamfodiacetat. 511573 10 15 20 25 30 35 2 comprises the following substances, as active substances: a) 5.0-10.0% by weight of orange interpen, b) 0.1-3.0% by weight of glycyrrhizin, c) 0.1- 1.5% by weight of xylitol, d) 1.0-10.0% by weight of cocoamphodiacetate.

Beredningen används för behandling av aphte.The preparation is used for the treatment of aphte.

Beredningen enligt föreliggande uppfinning kan administreras i form av munvatten, pasta, tabletter, kapslar eller tuggummi.The formulation of the present invention may be administered in the form of mouthwash, paste, tablets, capsules or chewing gum.

I en ytterliggare utföringsform av uppfinningen innefattar beredningen för behandling av aphte följande substanser förutom vatten: a) 5,0-10,0 vikt-% apelsinterpen, b) 0,1-3,0 vikt-% glycyrrhizin, c) 0,1-1,5 vikt-% xylitol, d) 1,0-10,0 vikt-% kokoamfodiacetat, e) 1,0-10,0 vikt-% polyetylen (20) sorbitan mono- stearat, f) 1,5-3,2 vikt-% karboximetylcellulosa, g) 0,2-0,5 vikt-% parahydroxibensoesyra metylester, h) 0,05-2,0 vikt-% natriumfluorid.In a further embodiment of the invention, the preparation for the treatment of aphthae comprises the following substances in addition to water: a) 5.0-10.0 wt.% Orange interpen, b) 0.1-3.0 wt.% Glycyrrhizin, c) 0.1 -1.5 wt% xylitol, d) 1.0-10.0 wt% cocoamphodiacetate, e) 1.0-10.0 wt% polyethylene (20) sorbitan monostearate, f) 1.5- 3.2% by weight of carboxymethylcellulose, g) 0.2-0.5% by weight of parahydroxybenzoic acid methyl ester, h) 0.05-2.0% by weight of sodium fluoride.

Beredningen innehåller även 1,0-5,0 vikt-% kiseldioxid, som polermedel.The preparation also contains 1.0-5.0% by weight of silica, as a polishing agent.

Beredningen enligt uppfinningen används för framställning av läkemedel för behandling av aphte.The preparation according to the invention is used for the preparation of medicaments for the treatment of aphthae.

Andra utföringsfomer av uppfinningen definieras av de underordnade kraven.Other embodiments of the invention are defined by the dependent claims.

Detalierad beskrivning av uppfinninqen.Detailed description of the invention.

Föreliggande uppfinning avser en beredning för behandling av olika former av aphte. Beredningen enligt föreliggande uppfinning innefattar apelsinterpener, vilka bl.a. ingår i apelsinolja. Apelsinterpenerna har visat sig vara synnerligen effektiva att fånga upp proteiner och polysackarider, och föra dessa bort fràn stället för angreppet. I den mest föredragna utföringsformen av före- 10 15 20 25 30 35 s11 373% 3 liggande beredning, ingår apelsinolja i beredningen.The present invention relates to a preparation for the treatment of various forms of aphthae. The preparation according to the present invention comprises orange interpenes, which i.a. included in orange oil. The orange interpenes have been shown to be extremely effective in capturing proteins and polysaccharides, and removing them from the site of attack. In the most preferred embodiment of the present 373% 3 formulation, orange oil is included in the formulation.

Apelsinolja är fettlösande och kan bl.a. lösa upp lipider i plack samt kan absorbera dessa.Orange oil is fat-dissolving and can i.a. dissolve lipids in plaques and can absorb them.

Kokoamfodiacetat är en amfotär tensid, som luck- rar upp placksiktet, därför möjliggör denna substans apelsinterpenernas goda effekt. Föreliggande beredning innefattar därför även kokoamfodiacetat. Tandkrämsformen innehåller ej natriumlaurylsulfat, som är en tensid. I en norsk vetenskaplig undersökning har G. Embery and G.Cocoa amphodiacetate is an amphoteric surfactant, which loosens the plaque screen, therefore this substance enables the good effect of orange interpenets. The present formulation therefore also includes cocoamphodiacetate. The toothpaste form does not contain sodium lauryl sulphate, which is a surfactant. In a Norwegian scientific study, G. Embery and G.

Rölla, Clinical and Biological Aspects of Dentifrices, sidorna 173-180, visat att natriumlaurylsulfat bidrar till aphte. I nämnda undersökning fann man att aphte slutade uppträda i ca. 70% av fallen, när natriumlauryl- sulfat uteslöts från tandkräm. De flesta av tandkrämerna, som finns på marknaden i dag innehåller natriumlauryl- sulfat.Rölla, Clinical and Biological Aspects of Dentifrices, pages 173-180, showed that sodium lauryl sulfate contributes to aphthae. In the said study it was found that aphte stopped appearing for approx. 70% of cases, when sodium lauryl sulphate was excluded from toothpaste. Most of the toothpastes on the market today contain sodium lauryl sulfate.

En annan substans, som gör föreliggande bered- ning gynnsam för behandling av aphte, är glycyrrhizin, som bl.a. ingår i extrakt från lakritsrot. Glycyrrhizin har bakterihämmande effekt och hämmar företrädesvis till- växt av streptococcus mutans. Glycyrrhizin är även pH- sänkande in vivo.Another substance which makes the present preparation favorable for the treatment of aphthae is glycyrrhizin, which i.a. included in extracts from licorice root. Glycyrrhizin has an antibacterial effect and preferably inhibits the growth of streptococcus mutans. Glycyrrhizin is also pH lowering in vivo.

En ytterligare substans, som ingår i föreliggan- de beredning, är xylitol. Xylitol verkar synergetiskt med ovan nämnda substanser och ökar således beredningens goda verkan. Bakterier tar upp xylitol, främst då andra sock- erarter är närvarande i ringa mängder. Xylitol verkar genom att hindra bakteriernas normala metabolism genom att bilda xylitolfosfat, som är giftigt för bakterierna och därför hindrar deras tillväxt. Bakterierna transpor- terar xylitolfosfat ut genom bakteriemembranen. Processen är mycket energikrävande, varför xylitolfosfatet ackumu- leras i bakterierna. En ytterligare fördel, som xylitol har, är att den inte bryts ner till organiska syror, som andra sockerarter gör. Med xylitol, som sötningsmedel, kan pH hållas på en mer gynnsam nivå och demineralisering av tandemaljen kan undvikas. 511 373 lO 15 20 25 30 35 4 För att undersöka verkan av kompositionen enligt uppfinningen gjordes en beredning i form av en tandkräm, där kompositionen innefattas. Beredningsformen i följande exempel begränsar således ej uppfinningen, men är till för att visa den form som administerades till de personer som ingick i studien.An additional substance included in the present formulation is xylitol. Xylitol acts synergistically with the above-mentioned substances and thus increases the good effect of the preparation. Bacteria take up xylitol, mainly when other sugars are present in small amounts. Xylitol works by inhibiting the bacteria's normal metabolism by forming xylitol phosphate, which is toxic to the bacteria and therefore prevents their growth. The bacteria transport xylitol phosphate out through the bacterial membranes. The process is very energy intensive, which is why the xylitol phosphate accumulates in the bacteria. An additional advantage that xylitol has is that it does not break down into organic acids, as other sugars do. With xylitol, as a sweetener, the pH can be kept at a more favorable level and demineralization of the tooth enamel can be avoided. 511 373 10 15 20 25 30 35 4 To investigate the effect of the composition according to the invention, a preparation in the form of a toothpaste was made, in which the composition is included. The dosage form in the following examples thus does not limit the invention, but is intended to show the form which was administered to the persons included in the study.

Beredning En tankräm iordningställdes genom att 10,0 g/kg glycyrrhizin och 22,0 g/kg karboximetylcellulosa torrbla- O ndades, varefter 100,0 g/kg glycerin 85 s-ig tillsattes under jämn omrörning tills blandningen var klumpfri. 50,0 g/kg Apelsinterpen, 50,0 g/kg polyetylen (20) sorbitan monostearat och 3,0 g/kg parahydroxibensoesyra metylester värmdes till 40'C under omrörning tills all parahydroxi- bensoesyra metylester var löst, varefter lösningen fick svalna till rumstemperatur. Den rumstempererade lösningen tillsattes blandningen under jämn omrörning. 10,0 g/kg Xylitoltol och 2,4 g/kg natriumfluorid löstes i 545,0 g/1 PQO och tillsattes blandningen. Tillsist löstes 50,0 g/kg kokoamfodiacetat i 127,6 g/l vatten och rördes ned i blandningen tillsammans med 30,0 g/kg kiseldioxid. Bland- ningen rödes därefter till en jämn pasta.Preparation A tank cream was prepared by dry mixing 10.0 g / kg glycyrrhizin and 22.0 g / kg carboxymethylcellulose, after which 100.0 g / kg glycerin 85 sg was added with steady stirring until the mixture was lump-free. 50.0 g / kg Orange interpen, 50.0 g / kg polyethylene (20) sorbitan monostearate and 3.0 g / kg parahydroxybenzoic acid methyl ester were heated to 40 ° C with stirring until all parahydroxybenzoic acid methyl ester was dissolved, after which the solution was allowed to cool to room temperature. The room temperature solution was added to the mixture with gentle stirring. 10.0 g / kg Xylitol tol and 2.4 g / kg sodium fluoride were dissolved in 545.0 g / l PQO and added to the mixture. Finally, 50.0 g / kg of cocoa amphodiacetate was dissolved in 127.6 g / l of water and stirred into the mixture together with 30.0 g / kg of silica. The mixture was then stirred into a smooth paste.

Pilotstudie För att undersöka effekten av beredningen, en- ligt föreliggande uppfinning, valdes 30 stycken personer med aftös stomatit i den orala slemmhinnan. Personerna i studien behandlades med tandkrämen utan extra vatten vid varje applikationsstillfälle dagligen under sex månader.Pilot study To investigate the effect of the preparation, according to the present invention, 30 people with aphthous stomatitis in the oral mucosa were selected. The subjects in the study were treated with the toothpaste without extra water at each application daily for six months.

Studien gjordes som en dubbel-blind studie. Pilotstudien visade att ett flertal personer, som behandlades med beredningen enligt föreliggande uppfinning upplevde en klar förbättring vid användandet av den aktuella tand- krämen. Detta resultat förstärks också av att ett flertal av patienter utanför studien som behandlats med tand- krämen rapporterar ett positivt resultat.The study was done as a double-blind study. The pilot study showed that a number of persons treated with the preparation according to the present invention experienced a clear improvement in the use of the toothpaste in question. This result is also reinforced by the fact that a number of patients outside the study who were treated with the toothpaste report a positive result.

Claims (8)

10 15 20 25 30 35 511 373 5 Patentkrav10 15 20 25 30 35 511 373 5 Patent claims 1. Beredning innehållande följande substanser: a) 5,0-10,0 vikt-% apelsinterpen, b) 0,1-3,0 vikt-% glycyrrhizin, c) 0,1-1,5 vikt-% xylitol, d) 1,0-10,0 vikt-% kokoamfodiacetat, för behandling av aphte.Preparation containing the following substances: a) 5.0-10.0% by weight of orange interpen, b) 0.1-3.0% by weight of glycyrrhizin, c) 0.1-1.5% by weight of xylitol, d ) 1.0-10.0% by weight of cocoamphodiacetate, for the treatment of aphthae. 2. Beredning enligt krav 1, kânnetecknad av att be- redningen även innhåller emulgeringsmedel, konsistens- givare, konserveringsmedel samt natriumfluorid.Formulation according to Claim 1, characterized in that the formulation also contains emulsifiers, solubilizers, preservatives and sodium fluoride. 3. Beredning enligt krav 2, kännetecknad av att beredningen även innehåller polermedel.Formulation according to Claim 2, characterized in that the formulation also contains polishing agents. 4. Beredning enligt krav 1, kännetecknad av att be- redningen även innhåller vatten, konserveringsmedel samt natriumfluorid,Preparation according to Claim 1, characterized in that the preparation also contains water, preservatives and sodium fluoride. 5. Beredning innehållande följande substanser: a) 5,0-10,0 vikt-% apelsinterpen, b) '0,l-3,0 vikt-% glycyrrhizin, C) 0,1-1,5 vikt-% xylitol, d) 1,0-10,0 vikt-% kokoamfodiacetat, e) 1,0-10,0 vikt-% polyetylen (20) sorbitan mono- stearat, f) 1,5-3,2 vikt-% karboximetylcellulosa, 9) 0,2-0,5 vikt-% parahydroxibensoesyra metylester, h) 0,05~2,0 vikt-% natriumfluorid, för behandling av aphte.Preparation containing the following substances: a) 5.0-10.0% by weight of orange interpen, b) 0.1-1.0% by weight of glycyrrhizin, C) 0.1-1.5% by weight of xylitol, d) 1.0-10.0% by weight of cocoamphodiacetate, e) 1.0-10.0% by weight of polyethylene (20) sorbitan monostearate, f) 1.5-3.2% by weight of carboxymethylcellulose, 9 ) 0.2-0.5% by weight of parahydroxybenzoic acid methyl ester, h) 0.05 ~ 2.0% by weight of sodium fluoride, for the treatment of aphthae. 6. Beredning enligt krav 5, kännetecknad av att 511 373 lO 6 beredningen även innehåller 1,0-5,0 vikt-% kiseldioxid, som polermedel.Formulation according to Claim 5, characterized in that the formulation also contains 1.0-5.0% by weight of silica, as polishing agent. 7. Beredning enligt något av kraven 1-6, känneteck- nad av att beredningen är i form av pasta, munvatten, tabletter, kapslar eller tuggummi.Preparation according to one of Claims 1 to 6, characterized in that the preparation is in the form of a paste, mouthwash, tablets, capsules or chewing gum. 8. Användning av beredningen enligt något av kraven 1-7, för beredning av läkemedel för behandling av aphte, företrädesvis aphte stomatitus.Use of the preparation according to any one of claims 1-7, for the preparation of medicaments for the treatment of aphte, preferably aphte stomatitus.
SE9704789A 1997-12-19 1997-12-19 Preparation for the treatment of aphte SE511373C2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE9704789A SE511373C2 (en) 1997-12-19 1997-12-19 Preparation for the treatment of aphte
PCT/SE1998/002366 WO1999032132A1 (en) 1997-12-19 1998-12-17 A preparation for the treatment of aphtae
AU19911/99A AU1991199A (en) 1997-12-19 1998-12-17 A preparation for the treatment of aphtae

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704789A SE511373C2 (en) 1997-12-19 1997-12-19 Preparation for the treatment of aphte

Publications (3)

Publication Number Publication Date
SE9704789D0 SE9704789D0 (en) 1997-12-19
SE9704789L SE9704789L (en) 1999-06-20
SE511373C2 true SE511373C2 (en) 1999-09-20

Family

ID=20409495

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704789A SE511373C2 (en) 1997-12-19 1997-12-19 Preparation for the treatment of aphte

Country Status (3)

Country Link
AU (1) AU1991199A (en)
SE (1) SE511373C2 (en)
WO (1) WO1999032132A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328537A1 (en) * 2011-06-23 2012-12-27 Cloonan Richard A Topical wound management formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA82361B (en) * 1981-02-06 1982-12-29 Biorex Laboratories Ltd Pharmaceutical composition for treating diseases of the oral cavity
US5531982A (en) * 1987-01-30 1996-07-02 Colgate Palmolive Company Antimicrobial oral composition
US5229425A (en) * 1990-06-01 1993-07-20 Doyle E. Chastain Process of producing reference bactericidal endpoint (RBE) limonene
JP3345133B2 (en) * 1992-12-21 2002-11-18 サンスター株式会社 Toothpaste composition

Also Published As

Publication number Publication date
SE9704789L (en) 1999-06-20
SE9704789D0 (en) 1997-12-19
AU1991199A (en) 1999-07-12
WO1999032132A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
EP1952801B1 (en) Oral cavity care curative and prophylactic composition
EP1040819B1 (en) Oral compositions comprising a potassium salt for reducing dental nerve and dentin sensitivity
DE60212673T2 (en) COMPOSITIONS FOR THE TREATMENT OF XEROSTOMY AND TREATMENT OF RELATED DISEASES
US9107920B2 (en) Extract of Trigonella foenum-graecum
DE2510412A1 (en) GINGIVITIS MEDICINAL PRODUCTS
SE461378B (en) COMPOSITION FOR MEDICAL TREATMENT AND PREVENTION TO PREVENT PARADONTOPATHY
CN106924106A (en) A kind of toothpaste for suppressing bacterial plaque and mitigate gingivitis
WO2018151567A1 (en) Toothpaste composition comprising jade component
US20150335549A1 (en) Oral Care Composition Containing Ionic Liquids
Wennström et al. The effect of mouthririses on parameters characterizing human periodontal disease
CN101829027B (en) Multifunctional mouthwash
CN108245552A (en) A kind of composition and its application for oral cavity
US5158764A (en) Dentifrice
WO2017086653A1 (en) Oral composition and method for preparing same
Southard et al. Effect of sanguinaria extract on development of plaque and gingivitis when supragingivally delivered as a manual rinse or under pressure in an oral irrigator
JPH1171253A (en) Salivation accelerator and composition for oral cavity
CN103599182A (en) Traditional Chinese medicine composition and preparation method thereof, and oral cavity cleaning and nursing product and preparation method thereof
SE511373C2 (en) Preparation for the treatment of aphte
CN1943625B (en) Oral sterilizing liquid
CN108175730B (en) Composition for oral cavity and application and preparation method thereof
CN114404522B (en) Chinese herbal medicine composition, gargle and preparation method
JP2005162633A (en) Salivation promoter, and oral cavity composition and food composition containing the same
KR0138248B1 (en) The oral cavity hygienic compositions
DE3104189C2 (en)
JP2007291117A (en) Artificial saliva